Neurovive Pharmaceutical AB Stock Price - NEVPF

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
SMALL CAP BASIC
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Neurovive Pharmaceutical AB NEVPF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00115 0.78% 0.14875 0.14875 0.14875 0.14875 0.1476 11:29:40
Bid Price Ask Price Spread Spread % News
0.12 0.1549 0.0349 22.53% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1 200 $ 0.148750 $ 30 8,084 0.0988 - 0.6688
Last Trade Time Type Quantity Stock Price Currency
09:30:06 200 $ 0.14875 USD

Neurovive Pharmaceutical AB Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 27.66M 185.95M $ -68.37M - -0.40 17.25M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Neurovive Pharmaceutical AB News

Latest NEVPF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NEVPF Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.14650.15380.120.125620020k7k0.002251.54%
1 Month0.13310.15820.110.142320067k11k0.0156511.76%
3 Months0.18520.18520.09880.148220067k15k-0.03645-19.68%
6 Months0.140.2093950.09880.149820067k9k0.008756.25%
1 Year0.50840.66880.09880.257710067k5k-0.35965-70.74%
3 Years0.60.850.09880.281010067k5k-0.45125-75.21%
5 Years6.111.60.09881.2593167k4k-5.95125-97.56%

Neurovive Pharmaceutical AB Description

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in preparation for a clinical phase II efficacy study for the prevention of moderate to severe traumatic brain injury (NeuroSTAT). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market with our without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program was in 2018 licenced to Fortify Therapeutics, a BridgeBio company, for local treatment of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).


Your Recent History
USOTC
NEVPF
Neurovive ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.